Northwest Biotherapeutics, Inc. Common stock
NWBO
NWBO was delisted on the 16th of December, 2016.
13 hedge funds and large institutions have $577K invested in Northwest Biotherapeutics, Inc. Common stock in 2021 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
30% more funds holding
Funds holding: 10 → 13 (+3)
22% more capital invested
Capital invested by funds: $472K → $577K (+$105K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KA
Kovack Advisors
Ft. Lauderdale,
Florida
|
+$37K |
| 2 |
MSAM
Moloney Securities Asset Management
Manchester,
Missouri
|
+$30.5K |
| 3 |
AA
AlphaMark Advisors
Ft. Wright,
Kentucky
|
+$21K |
| 4 |
Fisher Asset Management
Camas,
Washington
|
+$21K |
| 5 |
SPIA
Steward Partners Investment Advisory
New York
|
+$10K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EP
Eudaimonia Partners
Winchester,
Tennessee
|
-$7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MSAM
1
Moloney Securities Asset Management
Manchester,
Missouri
| $235K | +$30.5K | +20,720 | +15% |
|
|
OCG
2
Opus Capital Group
Cincinnati,
Ohio
| $66K | +$950 | +650 | +1% |
|
|
WJWM
3
Williams Jones Wealth Management
New York
| $57K | – | – | – |
|
|
GWI
4
Grace & White Inc
Ny,
New York
| $37K | – | – | – |
|
|
KA
5
Kovack Advisors
Ft. Lauderdale,
Florida
| $37K | +$37K | +25,000 | New |
|
|
AIP
6
Almanack Investment Partners
Wayne,
Pennsylvania
| $33K | – | – | – |
|
|
LDB
7
Lee, Danner & Bass
Nashville,
Tennessee
| $29K | – | – | – |
|
|
AA
8
AlphaMark Advisors
Ft. Wright,
Kentucky
| $21K | +$21K | +14,007 | New |
|
|
9
Fisher Asset Management
Camas,
Washington
| $21K | +$21K | +14,500 | New |
|
|
GG
10
Gofen & Glossberg
Chicago,
Illinois
| $19K | – | – | – |
|
11
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| $11K | – | – | – |
|
|
SPIA
12
Steward Partners Investment Advisory
New York
| $10K | +$10K | +7,000 | New |
|
|
AA
13
Ancora Advisors
Cleveland,
Ohio
| $1K | – | – | – |
|
|
EP
14
Eudaimonia Partners
Winchester,
Tennessee
| – | -$7K | -4,700 | Closed |
|
NWBO Hedge Fund Activity: Q2 2021 in Review
13 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q2 2021, worth a combined $577K — up 22% from $472K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new NWBO positions and 1 closed out — a net gain of 3 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Kovack Advisors, opening a new position worth an estimated $37K. The largest seller was Eudaimonia Partners, exiting entirely with an estimated $7K sold.
- 13 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q2 2021, up from 10 in Q1 2021.
- Funds reported $577K of Northwest Biotherapeutics, Inc. Common stock stock for Q2 2021, up 22% quarter-over-quarter.
- 4 funds opened new Northwest Biotherapeutics, Inc. Common stock positions in Q2 2021 and 1 closed out, a net change of +3 holders.
- The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q2 2021 was Kovack Advisors, an estimated $37K added.
- The largest Northwest Biotherapeutics, Inc. Common stock seller in Q2 2021 was Eudaimonia Partners, an estimated $7K sold.
Based on aggregated 13F filings for Q2 2021.